CTLA4 and melanoma: In fact, in a mouse melanoma model, treatment with a small molecule inhibitor of CAIX increased frequency of effector TH1 skewed CD4+ T cells and increased the response of these tumors to immune checkpoint therapy with anti-PD-1 and anti-CTLA-4 antibodies (74).